Extracorporeal life support allows lung transplant in anti-MDA5+ rapidly progressive-interstitial lung disease.
P. Bay (Creteil, France), M. Pineton De Chambrun (Paris, France), A. Roux (Siuresnes, France), V. Bunel (Paris, France), A. Combes (Paris, France), D. Israël Biet (Paris, France), B. Zuber (Paris, France), H. Nunes (Paris, France), Y. Allenbach (Paris, France), Y. Uzunhan (Paris, France)
Source: International Congress 2022 – COVID-19 acute respiratory distress syndrome and beyond
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Bay (Creteil, France), M. Pineton De Chambrun (Paris, France), A. Roux (Siuresnes, France), V. Bunel (Paris, France), A. Combes (Paris, France), D. Israël Biet (Paris, France), B. Zuber (Paris, France), H. Nunes (Paris, France), Y. Allenbach (Paris, France), Y. Uzunhan (Paris, France). Extracorporeal life support allows lung transplant in anti-MDA5+ rapidly progressive-interstitial lung disease.. 2314
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|